TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06736379: Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer

Sponsor: VLP Therapeutics · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 41 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06736379 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06736379 Rescue Dossier →